Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow‐up for patients with cervical malignancies
Open Access
- 28 May 2004
- Vol. 101 (1) , 164-171
- https://doi.org/10.1002/cncr.20349
Abstract
BACKGROUND During follow‐up for patients with cervical carcinoma, elevation of serum squamous cell carcinoma antigen (SCC‐Ag) levels in the absence of detectable recurrent lesions presents a diagnostic and therapeutic challenge. In the current prospective study, the authors evaluated the use of fluorine‐18‐labeled fluoro‐2‐deoxy‐D‐glucose (FDG) positron emission tomography (PET) to detect disease recurrence in this setting. METHODS Women with cervical carcinoma who experienced complete responses to primary treatment or salvage therapy and who had no evidence of recurrent disease as detected by conventional methods but had serum SCC‐Ag levels ≥ 2.0 ng/mL on 2 consecutive occasions were eligible for the study. PET was performed within 2 weeks after the completion of conventional studies for the assessment of recurrence. RESULTS Twenty‐seven consecutive patients were registered for the current study. PET findings were positive for 19 patients: 14 who had a distant lesion or lesions, 2 who had a local lesion or lesions, and 3 who had both local and distant lesions. Of these 19 patients, 17 were confirmed to have recurrent disease; the remaining two were found to be free of disease but had severe anthracosis in the PET‐positive mediastinal lymph nodes. Seven of the eight patients with negative PET findings were not found to have recurrent disease on follow‐up. Overall, PET detected FDG‐avid lesions in 17 (94%; P < 0.001) of the 18 patients with recurrent disease. Seven of these 18 patients received therapy with curative intent; complete control was achieved in 6, four of whom currently are alive and free of disease. The addition of PET in the current setting curbed the use of futile curative therapy and significantly increased overall survival for patients in the current cohort compared with a historical group of 30 consecutive patients who had elevated SCC‐Ag levels as a first sign of recurrence. CONCLUSIONS PET expedited the detection of recurrent cervical carcinoma in patients with unexplained elevation of SCC‐Ag levels. Such expedited detection may have positive effects on patient survival. Cancer 2004. © 2004 American Cancer Society.Keywords
This publication has 18 references indexed in Scilit:
- The impact of image fusion in resolving discrepant findings between FDG-PET and MRI/CT in patients with gynaecological cancersEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Value of Dual-Phase 2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography in Cervical CancerJournal of Clinical Oncology, 2003
- Prognostic Value of Positron Emission Tomography Using F-18-Fluorodeoxyglucose in Patients with Cervical Cancer Undergoing RadiotherapyGynecologic Oncology, 2002
- Monitoring of Serum Squamous Cell Carcinoma Antigen Levels in Invasive Cervical Cancer: Is It Cost-Effective?Gynecologic Oncology, 2002
- Metastatic Lymph Nodes in Patients with Cervical Cancer: Detection with MR Imaging and FDG PETRadiology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Squamous Cell Carcinoma Antigen: Clinical Utility in Squamous Cell Carcinoma of the Uterine CervixGynecologic Oncology, 1994
- Outcome of recurrent cervical carcinoma following definitive irradiationGynecologic Oncology, 1989
- Recurrent cervical carcinoma after radical hysterectomyGynecologic Oncology, 1988
- Radioimmunoassay for tumor antigen of human cervical squamous cell carcinomaCancer, 1977